Attached files
| file | filename |
|---|---|
| EX-23.1 - EXHIBIT 23.1 - Celator Pharmaceuticals Inc | v432927_exhx23x1.htm |
| EX-31.1 - EXHIBIT 31.1 - Celator Pharmaceuticals Inc | v432927_exhx31x1.htm |
| 10-K - 10-K - Celator Pharmaceuticals Inc | v432927_10k.htm |
| EX-31.2 - EXHIBIT 31.2 - Celator Pharmaceuticals Inc | v432927_exhx31x2.htm |
Exhibit 32.1
Certification Pursuant to
18 U.S.C. Section 1350
In connection with the annual report of Celator Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ending December 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
 |
|
|
| Date: March 21, 2016 | /s/ Scott T. Jackson Scott T. Jackson, Chief Executive Officer (principal executive officer) |
|
| Date: March 21, 2016 | /s/ Fred M. Powell Fred M. Powell, Vice President and Chief Financial Officer (principal financial and accounting officer) |